Heart-failure drug review leaves survival benefit uncertain in advanced kidney disease
Observational findings left survival and hospitalization benefits uncertain, despite better heart-pumping measurements in the end-stage kidney disease subgroup.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled observational studies did not establish lower mortality or fewer heart-failure hospitalizations with sacubitril/valsartan. In the end-stage kidney disease subgroup, the drug was associated with better heart-pumping measurements and lower systolic blood pressure. Those findings do not establish a survival benefit, and observational associations cannot demonstrate treatment effects.
The abstract omits comparator treatments and follow-up durations. Its imprecise estimates leave clinical benefit uncertain, and observational safety findings cannot confirm an absence of risk.
What researchers found
Combined mortality and heart-failure hospitalization: pooled odds ratio
Sacubitril/valsartan versus unspecified comparator treatments; follow-up timing was not reported. This estimates relative odds, not an absolute probability.
Reading the odds ratio
An odds ratio compares outcome odds between groups; one means equal odds. The interval includes that point, leaving the combined outcome uncertain. Mortality alone also showed no statistically significant difference.
What other outcomes add
The end-stage kidney disease subgroup showed better pumping measurements without a detected increase in high potassium or low blood pressure. Larger randomized trials are still needed to clarify efficacy and safety.
The original publication
The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction.
Tu KC, Weng YC, Liao CT et al.
Medicine (Baltimore) · 2026
- PubMed ID
- 41630233
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.